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1. Introduction 
In 2006, the prevalence of total cardiovascular disease in the US was 81.1 million people, out 
of which 17.6 million people had coronary heart disease (1). Heart failure, the progressive 
loss of cardiac contractile performance, affects approximately 5 million Americans, with 
estimated medical costs of $21-50 billion dollars per year (2). Current pharmacologic 
therapies focus on symptomatic treatment and halting the progression of the disease (1). 
Interventional or surgical procedures in the treatment of cardiovascular disease are often 
restricted to a limited time frame, with heart transplantation patients reliant upon donor 
hearts that are in great demand. 
In recent years, gene therapy studies have made significant progress in the successful 
treatment of numerous disease conditions using a variety of different approaches.   
Generally, gene therapy can be classified into two categories: germ line gene therapy where 
germ cells are modified by the introduction of functional genes which can subsequently be 
passed on to later generations, and somatic gene therapy where therapeutic genes are 
transferred into somatic cells of a patient.  Another form of gene therapy known as cell-
mediated gene therapy is where pluripotent stem cells or progenitor cells are delivered to 
the injured tissue/organ.  The focus of this article will be the modification of disease 
phenotypes through genetic engineering and transgenic expression of contractile and 
calcium regulatory proteins. 
2. Gene therapy and mouse models of disease 
The diseases that were initially targeted for gene therapy were associated with blood 
disorders or cancers.  For example, a decade ago, Pawlink et al demonstrated correction of 
sickle cell disease in a transgenic mouse model using a β globin gene variant being 
expressed in a lentiviral vector (3).  Hemophilia A was successfully treated in mouse and 
dog models using adenoviral vectors expressing factor VIII (4).  With the great promise of 
gene therapy in the treatment of disease, the field expanded rapidly with numerous mouse 
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models having a wide variety of diseases being the target of various therapeutic approaches.  
For example, mouse models of cystic fibrosis, atherosclerosis, various cancers, and several 
retinal diseases using different methodological approaches showed great promise for 
successful treatment (5-10).  Cardiovascular diseases have also been treated using gene 
therapy, targeting defined animal models of cardiac disease.  Some of these models of 
cardiac disease were associated with ischemic heart disease, heart failure, and hypertrophic 
cardiomyopathy. 
Currently, adeno-associated virus vectors are the most potent and promising vectors used 
for delivery of transgenes to the heart (11, 12).  They exhibit efficient uptake, stable long-
term expression of transferred genes, and tissue specificity dependent upon the viral 
serotype (13).  Of the 11 identified serotypes of adeno-associated viruses, types 6, 8, and 
specifically 9, have tropism for the heart (14, 15).  In addition to transgenes, these vectors can 
also deliver microRNAs to the heart which can regulate the simultaneous expression of 
multiple genes (11). 
In this review, we discuss the current studies using in vivo models of hypertrophic 
cardiomyopathy.  We describe various mouse models of hypertrophic cardiomyopathy and 
the different approaches that have been shown to be beneficial in improving cardiac 
pathology and function.  In using these models and testing various therapeutic approaches, 
a determination of the most effective means for improving cardiomyopathic disease can be 
elucidated. 
3. Familial hypertrophic cardiomyopathy 
Familial Hypertrophic Cardiomyopathy (FHC) is a genetic disease caused by autosomal 
dominant mutations in genes encoding sarcomeric contractile proteins.  Hundreds of 
disease causing mutations in any of 10 genes can result in FHC.  These mutations occur in 
both thick and thin filament proteins, including myosin heavy and light chains, myosin 
binding protein C, actin, troponins I and T, and α-tropomyosin.  Most of these mutations are 
missense mutations with single amino acid residue substitutions.  The overall prevalence of 
hypertrophic cardiomyopathy is approximately 1 in 500 people; however, many of these 
individuals exhibit mild symptoms only with late onset in life.  Pathologically, FHC is 
characterized by left and/or right ventricular hypertrophy that occurs in the absence of an 
increased external load, in addition to intraventricular septal hypertrophy (16).  Left 
ventricular outflow tract obstruction, diastolic dysfunction, and myocyte hypertrophy and 
disarray are often found.  Other common symptoms include myofibrillar disarray and 
fibrosis, increased calcium sensitivity of myofilaments, and cardiac arrhythmias that may 
lead to premature sudden death and/or heart failure.  An interesting feature is that these 
symptoms are quite variable, ranging from mild cardiac hypertrophy and no symptoms to 
marked hypertrophy with diastolic heart failure and sudden death (17).  These variable 
clinical phentoypes strongly suggest that a specific FHC mutation in a contractile protein 
seemingly can be modified by environmental factors and modifier genes. For example, 
pathological symptoms associated with FHC mutations in the troponin T gene appear to be 
minimal; however, most of these patients die of sudden cardiac arrest (18).   Patients with 
FHC mutations in the α-tropomyosin (α-Tm) gene exhibit a wide phenotypic range of 
symptoms.  In the United States, a small percentage (<5%) of FHC patients have mutations 
in α-Tm with relatively benign symptoms (19).  In Japan, the incidence of FHC patients with 
mutations in α-Tm is still relatively low, but the symptoms are more pathological (20, 21).  
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Interestingly, in Finland, FHC mutations in the α-Tm gene have a very high incidence rate 
(11%) among contractile proteins and are a leading cause of FHC; this is most likely due to a 
“founder’s effect” (22). The pathology of FHC with α-Tm mutations is quite severe in the 
Finnish population with a majority of the patients exhibiting a dramatic phenotype.  This 
variability in incidence and phenotype associated with the Tm cases in different populations 
most likely reflects environmental factors and modifier genes in altering the onset and 
pathological symptoms of FHC. 
There are 11 mutations in α-Tm that lead to FHC.  These mutations are scattered throughout 
the α-Tm protein, with the majority of them occurring in one of the troponin T binding 
regions (amino acids 175-190).  Since Tm is an α-helical coiled coil protein that dimerizes 
with itself, and binds to both actin and troponin T, the charge of each specific amino acid 
residue can play a critical role in both its own structure and in its interaction with its 
binding partners.  In order to gain a greater understanding of the molecular and 
physiological mechanisms that lead to FHC, we developed 2 transgenic mouse models that 
incorporate FHC mutations in α-Tm (23-25).  Since there is 100% amino acid conservation 
between mouse and human α-Tm sequence, the FHC mutant α-Tm protein in the transgenic 
mice is identical to the protein that is found in human patients.  The first model entailed a 
substitution of an asparagine for aspartic acid at codon 175 (Asp175Asn).  These mice 
develop a mild hypertrophic phenotype, coupled with systolic and diastolic dysfunction 
(23).  The cardiac myofilaments demonstrate increased calcium sensitivity, which is in 
agreement with human studies (26).  We also found a correlation between an increase in 
myofilament calcium sensitivity with a decrease in relaxation rate and a blunted response to 
β-adrenergic stimulation (27).  The second transgenic mouse model was a substitution of 
glycine for glutamic acid at codon 180 (Glu180Gly) (24, 25).  Pathological changes in the 
hearts of these mice are initially detected by 1 month and include ventricular concentric 
hypertrophy, fibrosis, and atrial enlargement.  These disease-associated changes 
progressively increase and initially resulted in lethality by 6 months of age; more recently, 
some of these mice survive much longer probably due to modifying genes introduced when 
mating the FHC Tm 180 mice with commercial non-transgenic control mice.  Physiological 
analyses show significant alterations in both contraction and relaxation of the heart, with 
increased sensitivity of the myofilaments to calcium.  Isolated cardiomyocytes from the 
Glu180Gly FHC mice also exhibit an increase in calcium sensitivity of force production (28).  
Thus, FHC associated Tm proteins alter myofilament structure and properties in individual 
cardiomyocytes that collectively cause the aberrant function of the entire heart which leads 
to hypertrophic cardiomyopathy. 
4. Rescue of cardiomyopathic mice by contractile proteins 
To determine whether it is possible to rescue FHC mice from their lethality and cardiac 
hypertrophic phenotype, we and others have taken several approaches (29-32).  The first 
approach was to target the myofilaments themselves through the incorporation of proteins 
that counteract the properties exhibited by the FHC mutant Tm 180 protein since 
myofilaments obtained from the hearts of FHC patients and animal models usually exhibit 
an increased sensitivity to calcium with respect to tension development.  This is also true for 
the FHC Tm 180 myofilaments.  To compensate for this increased calcium sensitivity, we 
generated a double-transgenic mouse expressing a chimeric Tm containing the α-Tm amino 
terminus and the carboxyl terminus of β-Tm, the fetal cardiac isoform (Chi 1) (30).  Previous 
www.intechopen.com
 
Gene Therapy Application 
 
88
work demonstrated that myofilaments from these Chi 1 mice have a decreased sensitivity to 
calcium (33, 34).  The double-transgenic mice which were created by crossing the 2 lines 
displayed normalized myofilament calcium sensitivity.  More importantly, the hearts of 
these mice exhibited a normal morphology with no pathological abnormalities and 
improved cardiac function (30).  These mice also displayed a normal life span.  These results 
demonstrate that alterations in calcium response by modifications in contractile proteins can 
prevent the pathological and physiological effects of FHC. 
Restrictive cardiomyopathy (RCM) is a human condition that displays clinical features of 
biatrial dilation, a restricted left ventricle, and sudden cardiac death.  Patients with this 
disease have mutations in cardiac z-line proteins, such as desmin and cardiac troponin I and 
T (35, 36).  Recently, a transgenic mouse model was generated (cardiac TnI193His) that 
displays many of the pathological changes that occur in human patients with RCM, 
including restrictive ventricles, biatrial enlargement, and sudden cardiac death (37, 38).  
These mice were crossed with another transgenic mouse line that expresses a cardiac TnI 
isoform that is truncated at the N-terminus (cTnI-ND) (31, 39); this is a naturally occurring 
TnI isoform that is found at low levels in normal hearts of all examined species.  Transgenic 
mice expressing the cTnI-ND isoform exhibit a normal cardiac phenotype with no evidence 
of hypertrophy or histological abnormalites (31).  Under hemodynamic stress and heart 
failure, the cTnI-ND isoform is increased in expression (40).  The double transgenic mice 
(cardiac TnI193His x cTnI-ND) rescued the lethal phenotype of the cardiac TnI193His RCM 
mutant mice; cardiac function was significantly improved and the myofilaments’ increased 
sensitivity to calcium was reversed (32).  These results, which are similar to those found 
with the FHC Tm180 rescued mice, suggest that calcium desensitization in myofibrils is a 
therapeutic option for the treatment of diastolic dysfunction. 
5. Rescue of cardiomyopathic mice through alterations in calcium handling  
In addition to rescuing cardiomyopathic conditions through treatment with compensatory 
contractile proteins, recent studies have also addressed whether proteins involved with 
calcium handling can play a role in improving the pathological effects of heart disease.  
Reports suggest that Serca2a overexpression can modulate cardiac hypertrophy due to 
removal of calcium from the myofilament region (41-43).  To test whether improvements in 
the hypertrophic phenotype can be achieved through increased Serca2 expression and/or 
activity, we recently treated the FHC Tm 180 mice with Serca2a, the protein involved in re-
sequestering calcium from the cytoplasmic space into the sarcoplasmic reticulum of the 
cardiomyocyte (44).  The approach that we implemented was gene transfer of Serca2a 
ligated to an adenoviral vector with injection into FHC Tm 180 neonatal hearts.  Results 
demonstrated that a single dose of Serca2a in 1-day-old mice improved the heart 
morphology, altered hypertrophic gene expression, and improved cardiac function.  
Histological results showed there was a significant decrease in fibrosis, coupled with a 
decrease in the heart weight:body weight ratio.  Molecular analysis shows that within the 
first 3 weeks, there is a significant decline in ANF and β-MHC expression in the Serca2a-
treated FHC Tm 180 mice.  In situ hemodynamic measurements show that by 3 months, the 
hearts from FHC Tm 180 mice treated with Serca2a have significantly improved their 
response to isoproterenol compared to control mouse hearts.  These results demonstrate that 
gene transfer of a single dose of Serca2a can delay the hypertrophic phenotype and improve 
cardiac function in an FHC mouse model that is associated with increased myofilament 
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calcium sensitivity.  As such, the study strongly suggests that Serca2a expression should be 
considered as a potential therapeutic approach in the treatment of FHC. 
The benefits for Serca2a overexpression on cardiac function has been demonstrated in both 
animal models and in human patients.  The sodium-calcium exchanger (NCX), along with 
Serca2a, are the two principle pumps used to remove cytosolic Ca2+ in the heart.  Both 
systolic and diastolic improvements occur with more efficient energy usage in removal of 
Ca2+ from the cytosol.  Results show that Serca2a removes twice as much cytosolic Ca2+ as 
the NCX for each ATP that is hydrolyzed (12).  During heart failure, there is decreased 
expression and function of Serca2a, which is compensated by increased NCX activity, which 
is a less efficient energy process. The ratio of Serca2a to NCX changes from approximately 
75:25 in the healthy human heart to 50:50 in the failing human heart (45).  Normalization of 
the Serca2a:NCX ratio in  heart failure by transgenic or gene therapy approaches appears to 
hold great therapeutic promise.  Studies show that delivery of Serca2a by gene transfer to 
experimental models of heart failure in sheep and swine can largely reverse cardiac 
dysfunction and improve systolic and diastolic performance of the heart (46, 47).  Recently, 
percutaneous administration of Serca2a was conducted in phase 1 and 2 clinical studies in 
humans (48, 49).  Heart failure patients were administered an adeno-associated virus 
expressing Serca2a.  Results showed a majority of patients exhibited marked improvements 
within 6 months, which included improved ejection fraction and end-systolic volume 
measurements.  Thus, the success of these human trials demonstrates that Serca2a may serve 
as a potential treatment modality for heart failure.  Phase 3 clinical trials are expected to be 
initiated soon. 
Another strategy that has been investigated in the treatment of hypertrophic mouse models 
has been to crossbreed these mice with phospholamban (PLB) knockout mice.  PLB is a 
protein that normally inhibits Serca2a activity of calcium re-sequestration into the 
sarcoplasmic reticulum.  Previous work demonstrated that when a heart failure mouse 
model due to overexpression of the β-adrenergic receptor was crossed with the PLB 
knockout mouse, systolic function was improved at 1 year; however, cardiac hypertrophy is 
still significant (50).  In a FHC model of myosin binding protein C, cross-breeding with the 
PLB knockout mice failed to rescue the hypertrophy, fibrosis and functional parameters of 
the FHC mutant hearts (51).  In a very recent study, we decided to cross the FHC Tm 180 
mice with the PLB knockout mice (52).  We hypothesized that since Tm is a thin filament 
protein in the sarcomere, which in FHC primarily affects diastolic function and calcium 
sensitivity, deletion of PLB may compensate for these altered physiological parameters by 
increasing the uptake of calcium into the sarcoplasmic reticulum and removing calcium 
from the myofilament space.  Our results demonstrated that PLB ablation in the FHC Tm 
180 mice rescued cardiac pathological changes and cardiac function for up to a year (52).  
The work with Serca2 overexpression and PLB knockout mice suggests that increased Ca2+ 
uptake by the sarcoplasmic reticulum may be a viable target for gene therapy in the 
treatment of FHC with thin filament contractile protein mutations. 
Previous studies from the Metzger laboratory demonstrated that a calcium buffer, 
parvalbumin, could also play a role in ameliorating some of the FHC Tm180 physiological 
alterations (53).  By crossing a parvalbumin transgenic mouse with the FHC Tm 180 mouse, 
they demonstrated that the decreased cardiac relaxation that occurs in the FHC mice was 
corrected.  In addition, the relaxation performance was also corrected in cardiomyocytes 
that were isolated from double transgenic mouse hearts.  Similarly, increased levels of 
parvalbumin expression were also able to rescue a slowed relaxation rate in FHC α-Tm 
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cardiomyocytes that expressed parvalbumin and the FHC mutant Tm that substituted 
valine for alanine at codon 63 (53).  Thus, these studies reinforce the concept that 
modification of calcium handling can rescue functional properties of FHC Tm myofilaments. 
6. Conclusions 
Familial hypertrophic cardiomyopathy is a common disease that is most often associated 
with mutations in the sarcomeric contractile proteins.  Diagnosis and treatment of this 
condition is still in its infancy, although there have been significant advances in the 
understanding of the genetic causes of this disease and the molecular pathways that trigger 
cardiac hypertrophy.  Recent studies implicate calcium itself, and the response to calcium by 
the sarcomere, as playing key roles in the development of hypertrophy.  Various methods 
have been successfully used in animal models of FHC to treat and rescue mice from 
hypertrophy and heart failure.  As such, they have demonstrated a “proof of principle” in 
the successful treatment of this disease.  Some of these treatment methods revolve around 
re-supplying contractile proteins that counteract the physiological consequences caused by 
the mutant FHC proteins.  For FHC mutations that occur in the thin filament and render the 
sarcomere most sensitive to calcium, the compensatory protein must exhibit properties 
associated with a decreased sensitivity to calcium.  Other effective treatments focus on 
removing calcium from the region of the myofilament by enhanced uptake by the 
sarcoplasmic reticulum or the buffering of calcium.  However, considering the large number 
of genes that activate different molecular pathways in contributing to the hypertrophic 
phenotype, it is unlikely that a single treatment strategy will be sufficient in addressing the 
various complexities of this disease.  As such, a wide variety of experimental approaches 
should be pursued so as to design the most effective treatment strategies for the diverse 
hypertrophic phenotypes that are manifest in human patients. 
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